List of Tables
- Table 1-01. Estimated number of US air passengers departing to the top 10 destination countries, 2015
- Table 2-01. Information necessary for a risk assessment during pretravel consultations
- Table 2-02. Vaccines to update or consider during pretravel consultations
- Table 2-03. Major topics for discussion during pretravel consultations
- Table 2-04. Recommended intervals between administration of antibody-containing products and measles-containing vaccine or varicella- containing vaccine
- Table 2-05. Recommended and minimum ages and intervals between vaccine doses
- Table 2-06. Travelers’ diarrhea treatment recommendations
- Table 2-07. Risk categories for acute mountain sickness
- Table 2-08. Ascent risk associated with various underlying medical conditions
- Table 2-09. Recommended medication doses to prevent and treat altitude illness
- Table 2-10. Comparison of water disinfection techniques
- Table 2-11. Microorganism size and susceptibility to filtration
- Table 2-12. Summary of field water disinfection techniques
- Table 2-13. Recommended strategies to reduce injuries while abroad
- Table 3-01. Mechanism of pathogenesis and typical clinical syndrome of Escherichia coli pathotypes
- Table 3-02. Vaccines to prevent hepatitis A
- Table 3-03. Interpretation of serologic test results for hepatitis B virus infection
- Table 3-04. Vaccines to prevent hepatitis B
- Table 3-05. Recommended dosage and duration of antiviral medications for treatment and prophylaxis of influenza A and B
- Table 3-06. Vaccine to prevent Japanese encephalitis (JE)
- Table 3-07. Risk for Japanese encephalitis (JE), by country
- Table 3-08. Reliable supply regimens for the treatment of malaria
- Table 3-09. Considerations when choosing a drug for malaria prophylaxis
- Table 3-10. Drugs used in the prophylaxis of malaria
- Table 3-11. Half-lives of malaria chemoprophylaxis drugs
- Table 3-12. Changing medications as a result of side effects during chemoprophylaxis
- Table 3-13. Food and Drug Administration recommendations for deferring blood donation in people returning from malarious areas
- Table 3-14. Meningococcal vaccines licensed in the United States
- Table 3-15. Criteria for preexposure immunization for rabies
- Table 3-16. Preexposure immunization for rabies
- Table 3-17. Postexposure immunization for rabies
- Table 3-18. Classification, primary vector, and reservoir occurrence of rickettsiae known to cause disease in humans
- Table 3-19. Tickborne encephalitis (TBE) vaccines licensed in Europe and Russia
- Table 3-20. Estimated proportion of MDR TB cases in high-burden countries
- Table 3-21. Vaccines to prevent typhoid fever
- Table 3-22. Countries with risk of yellow fever virus (YFV) transmission
- Table 3-23. Countries with low potential for exposure to yellow fever virus (YFV)
- Table 3-24. Vaccine to prevent yellow fever
- Table 3-25. Contraindications and precautions to yellow fever vaccine administration
- Table 3-26. Countries that require proof of yellow fever vaccination from all arriving travelers
- Table 3-27. Categories of recommendations for yellow fever vaccination
- Table 5-01. Illnesses associated with fever presenting in the first 2 weeks after travel
- Table 5-02. Common causes of fever, by geographic area
- Table 5-03. Common infections, by incubation period
- Table 5-04. Common clinical findings and associated infections
- Table 5-05. Ten most common skin lesions in returned travelers, by cause
- Table 8-01. Immunization of immunocompromised adults
- Table 8-02. Immunosuppressive biologic agents that preclude use of live vaccines
- Table 8-03. Special considerations for travelers with chronic medical illnesses
- Table 8-04. Diseases for which VFR travelers are at increased risk, proposed reasons for risk variance, and recommendations to reduce risks
- Table 8-05. Differences between military populations and civilian traveling populations
- Table 8-06. Differences between CDC recommendations and US military’s use of malaria chemoprophylaxis
- Table 8-07. Study-abroad resources
- Table 8-08. Top 10 countries of birth for newly arriving refugees and immigrants (from overseas locations), fiscal year 2014
- Table 8-09. Recommended postarrival laboratory screening tests for immigrants and refugees receiving medical care in the United States
- Table B-01. Travel vaccine summary
- Page created: June 13, 2017
- Page last updated: June 13, 2017
- Page last reviewed: June 13, 2017
-
Content source:
TOP